Evidence map›Paper›PMID 40612359›Full record

ArticleClinical and translational radiation oncology2025

Assessment of the impact of age on DIBH in radiotherapy based on the prospective GATTUM and B-REST trials.

Rebecca Moser, Lena Marie Buchecker, Jantje M Bohlen, Mathias Düsberg, Maximilian Aigner, Nina A Mayr, Jana Nano, Sophie T Behzadi, Sophia Kiesl, Marciana-Nona Duma and 3 more

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rebecca MoserDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Lena Marie BucheckerDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Jantje M BohlenDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Mathias DüsbergDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Maximilian AignerDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Nina A MayrInstitute of Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Oberschleißheim, Germany.
Jana NanoDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Sophie T BehzadiDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Sophia KieslDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Marciana-Nona DumaDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Markus OechsnerDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Stephanie E CombsDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Kai J BormDepartment of Radiation Oncology, TUM School of Medicine and Health, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Adjuvant radiotherapy (RT) of left sided breast cancer is increasingly performed in deep inspiration breath hold (DIBH). This technique requires active involvement and compliance of patients as well as pulmonary endurance. Since previous studies focused on female patients with a median age under 65 years to test practicability of DIBH and advantages in comparison to free breathing (FB), DIBH in elderly patients over 65 years remains mostly underexplored. This study aims to evaluate attitudes and feasibility of DIBH in elderly breast cancer patients. Methods: First a 14-item survey of 100 female breast cancer patients aged ≥65 years was conducted to assess their attitudes toward DIBH and their breath-hold capability. Secondly, we performed a matched-pair analyses using pooled data from the prospective GATTUM and B-REST trials to compare respiratory and dosimetric parameters during DIBH between patients aged ≥65 years (n = 30) and <65 years (n = 30). Results: According to the survey large majority of patients were interested in DIBH: 98 % stated that age should not be a criterion when selecting patients for DIBH, and 66 were able to hold their breath > 20 s. Based on the matched-pair analyses of the GATTUM and B-Rest trials, no significant differences were observed regarding breath hold amplitude, duration and stability, and in DIBH-induced dose reduction to organs at risk between elderly (≥65) (n = 30) and younger patients (n = 30). Conclusion: Based on our results age alone should not be used as a criterion for excluding patients from DIBH in the treatment of left-sided breast cancer.

Indexed as

Breast cancerDeep inspiration breath holdFree breathingRadiotherapy

Identifiers

PMID40612359
PMCPMC12223553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.